Adagene Inc.

Adagene Inc. a clinical stage immunotherapy company engages in the research development and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106 a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126 a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116 a human ligand-blocking anti-CTLA-4 mAb which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104 an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125 a novel anti-CSF-1R mAb which is in Phase I clinical trial; ADG206 a masked Fc engineered anti-CD137 agonistic POWERbody which is in preclinical; ADG153 a masked anti-CD47 IgG1 SAFEbody which is in preclinical stage for the treatment hematologic and solid tumors; ADG138 novel HER2xCD3 POWERbody which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152 a CD20xCD3 POWERbody which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou China.